Sugi Predict

Sugi Predict / Compounds / SCHEMBL7183573

SCHEMBL7183573

SCHEMBL7183573

Cc1cc(C)c(C(=O)c2ccccc2[P](=O)C(=O)c2c(C)cccc2C)c(C)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 4/20 0.39
▸ MEN1 O00255 2/20 0.39
▸ HPGD P15428 3/20 0.35
▸ LMNA P02545 1/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.35
▸ NPSR1 Q6W5P4 1/20 0.35
▸ MCOLN3 Q8TDD5 1/20 0.35
▸ CYP3A4 P08684 1/20 0.34
▸ CYP2C9 P11712 1/20 0.34
▸ BCL2L1 Q07817 1/20 0.34
▸ POLB P06746 1/20 0.33
▸ METAP2 P50579 1/20 0.33
▸ MYC P01106 1/20 0.33
▸ ALDH1A1 P00352 2/20 0.32
▸ HTT P42858 1/20 0.32
▸ KDM4E B2RXH2 1/20 0.32
▸ HSD17B10 Q99714 1/20 0.32
▸ GAA P10253 1/20 0.32
▸ CRHR1 P34998 1/20 0.32
▸ MAPK13 O15264 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7180500 1.00 KMT2A (0.39) KMT2AMEN1HPGDLMNASMN1; SMN2
SCHEMBL7174639 0.89 MEN1 (0.37) KMT2AMEN1HPGDLMNASMN1; SMN2
SCHEMBL7187205 0.89 KMT2A (0.39) KMT2AMEN1HPGDLMNASMN1; SMN2
SCHEMBL7190480 0.88 MEN1 (0.47) KMT2AMEN1HPGDLMNACYP2C9
SCHEMBL7181110 0.88 MEN1 (0.47) KMT2AMEN1LMNACYP2C9ALDH1A1
SCHEMBL7184426 0.88 MEN1 (0.36) KMT2AMEN1HPGDLMNASMN1; SMN2
SCHEMBL7188528 0.88 KMT2A (0.38) KMT2AMEN1HPGDLMNASMN1; SMN2
SCHEMBL7180124 0.87 MEN1 (0.38) KMT2AMEN1HPGDLMNASMN1; SMN2
SCHEMBL7186638 0.86 MEN1 (0.42) KMT2AMEN1HPGDLMNASMN1; SMN2
SCHEMBL7182861 0.86 KMT2A (0.35) KMT2AMEN1HPGDLMNACYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 — — US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 — — US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 — — US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 KMT2A 1586/4885MEN1 2312/4885HPGD 3983/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 KMT2A 956/4885MEN1 2263/4885HPGD 4041/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.